CYBERDYNE Co., Ltd. (Tsukuba City, Ibaraki Prefecture, President: Yoshiyuki Sankai, hereinafter referred to as “the Company”) announced on May 7, 2024 (US time) that the U.S. Food and Drug Administration (FDA) will newly treat medical HAL® lower limb type (hereinafter referred to as medical HAL®) with cerebral palsy, HTLV-1-associated myelopathy (HAM), We are pleased to announce that we have received approval to expand the indication for hereditary spastic paraplegia and a small model that will be available to patients with a height of 100 cm.
By Google Translate
